COMMUNIQUÉS West-GlobeNewswire

NexLife Includes a Licensed Doctor, a Nutrition Plan and Health Check-Ins After Treatment Starts in Every Compounded GLP-1 Subscription
23/09/2026
Every NexLife compounded GLP-1 subscription includes a doctor's review, a personalized nutrition plan and a 1:1 fitness coaching call alongside the medication. Ongoing care runs through Care 360, giving members 24/7 [...]
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
23/09/2026
- Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders - REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that it has [...]
Cheryl Polmatier Joins U.S. Oral Surgery Management as SVP of Payer Relations
23/09/2026
IRVING, Texas, Sept. 23, 2026 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management ( USOSM ) – a management services organization that exclusively serves premier oral and maxillofacial surgeons – has named Cheryl Polmatier [...]
NEXGEL Announces Dial-In Details for Investor Update Call
23/09/2026
LANGHORNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a company with a patient centric medical technology sales and marketing team working closely with clinicians [...]
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
23/09/2026
THIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company [...]
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
23/09/2026
SUNNYVALE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided [...]
Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies
23/09/2026
SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed test (LDTs), today announced [...]
IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference
23/09/2026
ORLANDO, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it [...]
Pycnogenol® Offers Clinically Backed Cognitive Support Across Generations
23/09/2026
Research on French maritime pine bark extract spans children, students, working professionals and older adults looking to stay mentally sharp GENEVA, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Brain health is no longer a [...]
Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
23/09/2026
One cGMP batch, manufactured in-house under Optimi's Health Canada Drug Establishment Licence, supplies both the Canadian trial and Australian clinics VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- [...]
Cannabix’s BreathLogix Alcohol Screening Solution Enters U.S. Manufacturing Workplace Market with Deployment at Alabama Facility
23/09/2026
VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing [...]
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
23/09/2026
Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108 Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis [...]
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
23/09/2026
The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression [...]
Parexel Transforms Functional Service Provider (FSP) Model to Improve R&D Productivity and Enhance Post-Approval Product Lifecycle Services for Biopharmaceutical Companies
23/09/2026
Integrated FSP model pairs specialist global talent with ParexelAI-enabled technology and operational expertise, enabling sponsors to better flex capacity as pipelines shift RALEIGH, N.C., Sept. 23, 2026 (GLOBE NEWSWIRE [...]
Actinogen XanaMIA pivotal Alzheimer’s disease trial completes final patient visit, with topline results on track for November
23/09/2026
This phase 2b/3, double-blind trial of oral Xanamem in 247 participants with mild to moderate Alzheimer’s disease and elevated pTau181 evaluates the potential benefit of targeting excess cortisol in the brain over a 36- [...]
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
23/09/2026
Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial Opportunity HOUSTON, Sept. 23, 2026 (GLOBE [...]
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
23/09/2026
ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of [...]
BioAro Launches AI-Assisted LONgevity+™ Bioactives in the U.S. and U.K.
23/09/2026
Following its Dubai debut, BioAro brings its precision longevity portfolio to two major global health and wellness markets NEW YORK and LONDON, Sept. 23, 2026 (GLOBE NEWSWIRE) -- The longevity industry has no shortage [...]
SOTIO Advances SOT106 with Dual FDA Designations, Further Positioning the Program as a Potential Best-in-Class ADC for Sarcoma
23/09/2026
Fast Track Designation granted for treatment of osteosarcoma Orphan Drug Designation granted for treatment of soft tissue sarcoma Multiple FDA designations underscores the promise of SOT106 and strengthens the program’s [...]

Pages